BridgeBio Pharma (BBIO) Debt Ratio (2018 - 2026)

BridgeBio Pharma (BBIO) reported Debt Ratio of 2.33 for Q1 2026, up 194.92% sequentially from 0.79 in Q4 2025.

BridgeBio Pharma (BBIO) Debt Ratio (2018 - 2026) Analysis & Trends

BridgeBio Pharma (BBIO) has 9 years of Debt Ratio data on file, last reported at 2.33 in Q1 2026.

For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 2.33; the trailing twelve-month figure through Mar 2026 stood at 2.33 (changed N/A YoY), and the FY2025 full-year result was 0.79, up 66.39% from the prior year.
Debt Ratio grew to 2.33 in Q1 2026, from 0.79 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 2.33 in Q1 2026 to a low of 0.48 in Q4 2024.
A 5-year average of 0.85 and a median of 0.67 in 2023 frame the typical range for Debt Ratio.
Across the five-year window, Debt Ratio soared 518.25% in 2022 and slumped 41.78% in 2024, its largest moves.
Tracing BBIO's Debt Ratio over 5 years: stood at 0.69 in 2022, then advanced by 18.12% to 0.82 in 2023, then tumbled by 41.78% to 0.48 in 2024, then jumped by 66.39% to 0.79 in 2025, then soared by 194.92% to 2.33 in 2026.
Business Quant data shows BBIO's Debt Ratio at 2.33 in Q1 2026, 0.79 in Q4 2025, and 2.01 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn	2.33

Download Data